硫酸氢氯吡格雷片联合替格瑞洛对冠心病PCI术后患者血小板最大聚集率的影响  

Effect of Clopidogrel Bisulfate Tablet Combined with Ticagrelor on Maximum Platelet Aggregation Rate in Patients with Coronary Heart Disease after PCI

作　　者：谭铭龙 沈铭贤 邓福 TAN Minglong;SHEN Mingxian;DENG Fu(Department of Internal Medicine,Taihe Branch of Southern Hospital,Guangzhou,Guangdong Province,510540 China)

机构地区：[1]南方医院太和分院内科,广东广州510540

出　　处：《系统医学》2023年第19期85-88,共4页Systems Medicine

摘　　要：目的探讨硫酸氢氯吡格雷片联合替格瑞洛对冠状动脉粥样硬化性心脏病(简称冠心病)经皮冠状动脉介入术(percutaneous coronary intervention,PCI)术后患者血小板最大聚集率(maximum platelet aggregation rate,MPAR)的影响。方法选取2019年6月—2021年1月南方医院太和分院内科行PCI治疗的83例冠心病患者,以随机数表法分为单一组40例及联合组43例,两组患者均于常规治疗基础上给予硫酸氢氯吡格雷片治疗,联合组在此基础上加用替格瑞洛,持续治疗3个月。对比两组患者治疗前及治疗3个月后血小板功能变化,并记录两组患者用药随访期间主要不良心脏事件(major adverse cardiac events,MACE)及出血事件发生情况。结果两组患者治疗3个月后血小板功能明显低于治疗前,差异有统计学意义(P<0.05),联合组血小板功能明显低于单一组,差异有统计学意义(P<0.05)。联合组治疗3个月内MACE总发生率为4.65%低于单一组的22.50%,差异有统计学意义(χ^(2)=5.743,P=0.017)。两组患者治疗3个月内出血发生率比较,差异无统计学意义(P>0.05)。结论硫酸氢氯吡格雷片联合替格瑞洛可有效抑制冠心病PCI术后患者血小板活化及聚集,两者联合使用可进一步提高抑制效果,并防止MACE发生。Objective To investigate the effect of clopidogrel bisulfate tablets combined with ticagrelor on the maximum platelet aggregation rate(MPAR)in patients with coronary atherosclerotic heart disease(coronary heart disease)after percutaneous coronary intervention(PCI).Methods A total of 83 patients with coronary heart disease who underwent PCI in the Department of Internal Medicine of Taihe Branch of Southern Hospital from June 2019 to January 2021 were selected and divided into single group(40 cases)and combined group(43 cases)by random number method.Both groups were treated with clopidogrel bisulfate tablets on the basis of conventional treatment,and the combined group was treated with ticagrelor on the basis of this treatment for 3 months.The changes of platelet(PLT)function before treatment and after 3 months of treatment were compared between the two groups,and the occurrence of major adverse cardiac events(MACE)and bleeding events were recorded during medication follow-up.Results After 3 months of treatment,the platelet function of the two groups was significantly lower than before treatment,the difference was statistically significant(P<0.05),and the platelet function of the combined group were significantly lower than those in single group,the difference was statistically significant(P<0.05).The total incidence of MACE within 3 months in the combined group was 4.65%lower than that in the single group 22.50%,and the difference was statistically significant(χ^(2)=5.743,P=0.017).There was no significant difference in the incidence of hemorrhage between the two groups within 3 months after treatment(P>0.05).Conclusion Both clopidogrel bisulfate tablets and ticagrelor can effectively inhibit PLT the activation and aggregation of blood platelet in patients with coronary heart disease after PCI,and the combination of the two can further improve the inhibitory effect and prevent the occurrence of MACE.

关 键 词：硫酸氢氯吡格雷片 替格瑞洛 冠心病 经皮冠状动脉介入术 血小板最大聚集率 

分 类 号：R4[医药卫生—临床医学]